CD8A and cancer: Enhancing the efficacy of ICB therapy could be achieved by adjusting the metabolic profile of effector T cells, curtailing glycolysis, or reducing LDHA levels in cancer cells, thereby improving the functionality of activated CD8+ T cells in the tumor microenvironment.310 Studies have illustrated that ICB can suppress immune cell metabolism by inhibiting glycolysis while boosting fatty acid oxidation and lipolysis.311 The integration of metabolic interventions with ICB presents a novel avenue for enhancing anti-tumor efficacy.